Carol Lindstrom
Carol Lindstrom's purchase track record
Carol Lindstrom has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/27/2026 | EFOR | $5K | +2.7% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
EFOR: Workday Screening, Analyst Targets, Cash‑Stock Alerts. Everforth is adding screening tools to its Workday platform, a move that deepens its consulting‑led strategy. BMO Capital and Truist Securities have lifted their price targets to $41 and $45, respectively, while analysts note the company’s earnings outlook. The firm is also listed among three cash‑producing stocks flagged for warning signs, adding a layer of caution for investors.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Genpact Highlighted in Recent Stock Analysis Articles. Recent articles from Yahoo and ChartMill have discussed Genpact as a potential option for long-term investors. These pieces focus on the company's quality and position within the services sector. The stock currently trades near a key support level, with analysts maintaining a wide range of price targets.
Transaction History
| EXPO | ▲ Buy | Option Exercise | 2,009 | — | 6/3/2026 | View on chart |
| EFOR | ▲ Buy | Open Market | 240 | $5K | 4/27/2026 | View on chart |
| EFOR | ▲ Buy | Open Market | 7 | $141 | 4/27/2026 | View on chart |
| G | ▲ Buy | Grant | 6,521 | $0 | 4/23/2026 | View on chart |
| EFOR | ▲ Buy | Grant | 4,500 | $210K | 1/2/2026 | View on chart |
| G | ▼ Sell | Open Market | 2,326 | $100K | 8/12/2025 | View on chart |
| EXPO | ▲ Buy | Option Exercise | 1,525 | — | 6/4/2025 | View on chart |
| G | ▲ Buy | Grant | 4,825 | $0 | 5/22/2025 | View on chart |
| G | ▼ Sell | Open Market | 4,916 | $267K | 2/11/2025 | View on chart |
| EFOR | ▲ Buy | Grant | 2,232 | $185K | 1/2/2025 | View on chart |
| G | ▼ Sell | Open Market | 3,218 | $150K | 11/12/2024 | View on chart |
| EXPO | ▼ Sell | Open Market | 1,039 | $100K | 11/4/2024 | View on chart |
| EFOR | ▼ Sell | Open Market | 1,060 | $99K | 10/25/2024 | View on chart |
| EXPO | ▼ Sell | Open Market | 932 | $100K | 7/30/2024 | View on chart |
| EXPO | ▲ Buy | Option Exercise | 1,506 | — | 6/5/2024 | View on chart |
| G | ▲ Buy | Grant | 6,707 | $0 | 5/2/2024 | View on chart |
| EFOR | ▼ Sell | Open Market | 1,000 | $97K | 4/30/2024 | View on chart |
| EFOR | ▲ Buy | Grant | 1,933 | $185K | 1/2/2024 | View on chart |
| EXPO | ▲ Buy | Option Exercise | 1,489 | — | 6/7/2023 | View on chart |
| G | ▲ Buy | Grant | 4,916 | $0 | 5/4/2023 | View on chart |
| G | ▼ Sell | Open Market | 4,308 | $205K | 2/14/2023 | View on chart |
| EXPO | ▼ Sell | Open Market | 1,875 | $200K | 2/7/2023 | View on chart |
| EFOR | ▲ Buy | Grant | 2,243 | $185K | 1/3/2023 | View on chart |
| G | ▼ Sell | Open Market | 2,703 | $123K | 11/14/2022 | View on chart |
| G | ▼ Sell | Open Market | 2,409 | $102K | 6/15/2022 | View on chart |
| EXPO | ▲ Buy | Option Exercise | 1,474 | — | 6/1/2022 | View on chart |
| G | ▲ Buy | Grant | 4,829 | $0 | 5/19/2022 | View on chart |
| EFOR | ▲ Buy | Grant | 1,209 | $150K | 1/3/2022 | View on chart |
| EXPO | ▼ Sell | Open Market | 880 | $100K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Exponent stock viewed as reasonable versus cash flow value
A recent Yahoo analysis notes that Exponent’s share price appears reasonable when compared with its cash‑flow generation. The view aligns with the company’s current valuation metrics, including a trailing P/E of about 30.6 and a dividend yield of 1.34%. Analysts’ average target price of $84 sits within the recent 52‑week range, suggesting the market’s expectations are consistent with the cash‑flow assessment.
Exponent stock viewed as reasonable versus cash flow value. A recent Yahoo analysis notes that Exponent’s share price appears reasonable when compared with its cash‑flow generation. The view aligns with the company’s current valuation metrics, including a trailing P/E of about 30.6 and a dividend yield of 1.34%. Analysts’ average target price of $84 sits within the recent 52‑week range, suggesting the market’s expectations are consistent with the cash‑flow assessment.